Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02956317
Recruitment Status : Unknown
Verified November 2017 by Sirnaomics.
Recruitment status was:  Recruiting
First Posted : November 7, 2016
Last Update Posted : December 2, 2017
Sponsor:
Information provided by (Responsible Party):
Sirnaomics

Brief Summary:
This is a randomized, double-blind, within-subject placebo controlled study to evaluate the safety and efficacy of various doses of STP705 administered as intradermal Injection in subjects with hypertrophic scar. The goals are to determine the recommended Phase 2 dose, the pharmacokinetics and pharmacidynamics parameters, and conduct analysis of biomarkers common to the scar formation pathway.

Condition or disease Intervention/treatment Phase
Hypertrophic Scar Drug: STP705 Drug: Placebo Phase 1 Phase 2

Detailed Description:

This single-center, randomized, double-blind, within-subject placebo controlled study is designed to evaluate the safety and efficacy of various doses of STP705 administered as intradermal injection in subjects with linear hypertrophic scar.

Twenty four subjects will be divided equally among 3 cohorts (20, 30 and 40 μg/cm2/day dose level) of 8 subjects each. Each subject will receive both active (STP705) and control (Placebo) treatment twice a week for a total of 4 weeks. The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.

Subjects will be confined to clinic or research unit for 24 hours post-dosing after the first treatment administration for the serial PK assay and the blood sample will be collected at the following post-dosing times: 30 min, 1 hr, 2 hrs, 3 hrs, 4 hrs, 5hrs, 6 hrs, 8 hrs, 12 hrs, 16 hrs, 24 hrs, 32 hrs and 36 hrs. Post-dosing ECG will be performed 6 hours (±1 hr) after the first study drug administration and vital signs will be monitored every 2h till 12h post-administration. Adverse events and medications will be monitored throughout the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Within-Subject Placebo Controlled Study to Evaluate the Safety and Efficacy of Various Doses of STP705 Administered as Intradermal Injection in Subjects With Hypertrophic Scar.
Study Start Date : January 2017
Estimated Primary Completion Date : November 2017
Estimated Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scars

Arm Intervention/treatment
Active Comparator: STP705
Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.
Drug: STP705
The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
Other Name: COTSIRANIB

Drug: Placebo
Normal Saline

Placebo Comparator: Placebo
Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar
Drug: STP705
The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
Other Name: COTSIRANIB

Drug: Placebo
Normal Saline




Primary Outcome Measures :
  1. Differences among the 3 dosage Groups in 24 Patients' appearance of the scar from baseline evaluated by Patient and Observer Scar Assessment Scale (POSAS) [ Time Frame: 32 weeks ]

Secondary Outcome Measures :
  1. Change in appearance of the scar from baseline evaluated by Physician Global Assessment using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS) at T4, T8, FU1, FU2 and FU3 visits. [ Time Frame: 32 weeks ]
    Physician global assessment will be performed using the overall opinion question of the POSAS scale. Physicians will be asked to rate the severity of the participant's scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (worst imaginable scar). Within participant treatment difference from baseline will be assessed separately for Site A and Site B.

  2. Change in appearance of the scar from baseline evaluated by Physician Scar Assessment using Complete Patient and Observer Scar Assessment Scale (POSAS) at T4, T8, FU1, FU2 and FU3 visits. [ Time Frame: 32 weeks ]
    Within participant treatment difference from baseline will be assessed separately for Site A and Site B.

  3. Change in appearance of the scar from baseline evaluated by Patient Global Assessment Using Overall Opinion of Patient and Observer Scar Assessment Scale (POSAS) at T4, T8, FU1, FU2 and FU3 visits [ Time Frame: 32 weeks ]

    Patient global assessment was performed using the overall opinion question of the POSAS scale.

    Participants were asked to rate the severity of their scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (very different from normal skin). Within participant treatment difference from baseline will be assessed separately for Site A and Site B.


  4. Change in volume/size of the scar from baseline evaluated by volumetric measurement using 3D camera at T4, T8, FU1, FU2 and FU3 visits [ Time Frame: 32 weeks ]
    Within participant treatment difference from baseline will be assessed separately for Site A and Site B.


Other Outcome Measures:
  1. Safety and Tolerability as measured by adverse events (AEs) and clinically relevant changes in laboratory values, vital signs, electrocardiograms (ECGs), and physical examination variables [ Time Frame: 32 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is able to understand and willing to conform to the study procedures and has signed the informed consent form (ICF).
  2. Subject is male or female, between the ages of 18 and 60 years, inclusive.
  3. Subject with a hypertrophic scar that meet all of the following criteria:

    • linear scar, ≥5 to ≤40 cm in length (Cohort A), ≥5 to ≤50 cm in length (Cohort B), ≥5 to ≤60 cm in length (Cohort C)
    • present for minimum 6 months and no greater than 24 months
    • located anywhere in the body except on the face or front of neck
    • resulting from surgical or traumatic injury
  4. Subject is judged, by the Investigator, to be healthy as evidenced by lack of clinically significant abnormal findings on medical history, physical examination, electrocardiogram, vital signs, and clinical laboratory tests.
  5. Subject is willing and able to complete the entire course of the trial and to comply with the trial instructions.
  6. Subject, if female of child-bearing potential, has a negative serum pregnancy test at screening and a negative urine pregnancy test at prior to treatment and willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence) throughout the study.

Exclusion Criteria:

  1. Subjects identified as having keloid or burn scars
  2. Subjects who are positive for hepatitis B surface antigen (HbsAg), hepatitis C antibody and HIV.
  3. Concurrent use of corticosteroids (including inhaled steroids) and COX-2 inhibitors
  4. Are immuno-compromised (HIV infected, cancer and other disease affecting the basal immune response)
  5. Clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurological, psychiatric, immunological, gastrointestinal, hematological, or metabolic disease that is, in the opinion of the Investigator, not stabilized or may otherwise impact the results of the study.
  6. Known allergy or hypersensitivity to the study drug(s) or one of the ingredients of the formulation.
  7. Any infection or wound in the area to treat.
  8. Female subjects who are pregnant or breast-feeding.
  9. Participation in a clinical study involving administration of an investigational compound within the past 30 days.
  10. Existence of any surgical, medical or laboratory condition that, in the judgment of the clinical investigator, might interfere with the safety, distribution, metabolism or excretion of the drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02956317


Contacts
Layout table for location contacts
Contact: Michael Molyneaux, MD 217-371-8661 michaelmolyneaux@simaomics.com

Locations
Layout table for location information
United States, California
WCCT Global Recruiting
Cypress, California, United States, 90630
Contact: Michelle Ababa, M.D.    714-252-0700 ext 1068      
Sponsors and Collaborators
Sirnaomics

Layout table for additonal information
Responsible Party: Sirnaomics
ClinicalTrials.gov Identifier: NCT02956317     History of Changes
Other Study ID Numbers: SRN-705-001
First Posted: November 7, 2016    Key Record Dates
Last Update Posted: December 2, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertrophy
Cicatrix, Hypertrophic
Cicatrix
Fibrosis
Pathologic Processes
Pathological Conditions, Anatomical